jueves, 2 de febrero de 2017
2022 Ranking, Top 20 Pharma
When we published our annual EvaluatePharma® World Preview report in September 2016, we showed a positive outlook through 2022 where scientific innovation combined with more targeted R&D and commercial strategies were likely to lead to a period of sustained growth (6.1% CAGR3 2015-224 ).
A few months later the scenario has not materially changed.
If we look at the Top 20 pharmaceutical companies, EvaluatePharma® aggregated consensus forecasts predict a CAGR of 4.1% through 2022.
Within this group, companies such as Shire, Celgene and BMS stand out where expected growth far exceeds the average of this cohort. On the lower end of the spectrum, Gilead’s long-term revenue outlook is heavily affected by the rapid maturing of its Hepatitis C franchise.
Asi pensaron sería a 2016..